<DOC>
	<DOC>NCT00291408</DOC>
	<brief_summary>The purpose of the study is to compare histone acetyltransferase (HAT) and histone deacetylase (HDAC) expressions and activities in induced sputum macrophages obtained from patients with moderate to severe COPD and age-matched normal non-smokers</brief_summary>
	<brief_title>Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Inclusion CriteriaHealthy nonsmokers Nonsmoking volunteer aged 40 75 years (age matched to COPD patients) Normal spirometry (normal FEV1/FVC ratio &gt;70% and FEV1&gt;80% predicted) Subjects are able to give informed consent Inclusion CriteriaCOPD patients (stage IIIII according to the GOLD guidelines) Current and/or exsmokers with no less than 10 packyear smoking history aged 40 75 years FEV1 greater than or equal to 30% and less than 80% of predicted (the upper value is a prostbronchodilator value) FEV1/FVC &lt; 70% Patients with stable COPD Inhaled Corticosteroid (ICS) treatment, if exists, must be stopped for 2 weeks prior the study treatment Longacting beta2agonists and theophylline need to be stopped at least 3 days before runin , but anticholinergics will be allowed throughout the study The subjects are able to give informed consent Exclusion CriteriaHealthy nonsmokers Pregnancy, breastfeeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator Upper respiratory infection within the last 4 weeks Subjects who have received research medication within the previous one month Subjects unable to give informed consent Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study. Exclusion CriteriaCOPD patients Evidence of asthma Bronchodilator reversibility &gt; 12% Pregnancy, breastfeeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator Patients who have had oral steroids within 8 weeks prior to the screening visit. Patients who are already on ICS and in which it is considered unsafe (as judged by the Investigator) to stop this treatment for the study period. Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the screening visit. Upper respiratory infection within the last 4 weeks Subjects who have received research medication within the previous one month Subjects unable to give informed consent Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Patients with significant comorbidities as judged by the investigator Any other respiratory disease, which is considered by the investigator to be clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>